10 / 21
Characteristics
Efficacy population (n=106)
Safety population (n=377)
BRCA
gene mutation, % (n)
BRCA
1
63.2 (67)
23.6 (89)
BRCA
2
36.8 (39)
14.3 (54)
No mutation
0
62.1 (234)
Median number of prior chemotherapies (range)
3 (2–6)
2 (1–7)
1 prior chemotherapy, % (n)
0
33.7 (127)
2 prior chemotherapies, % (n)
38.7 (41)
22.5 (85)
≥3 prior chemotherapies, % (n)
61.3 (65)
43.8 (165)
Median number of platinum-based therapies (range)
2 (2–5)
2 (1–5)
1 prior platinum-based therapy, % (n)
0
34.7 (131)
2 prior platinum-based therapies, % (n)
56.6 (60)
38.2 (144)
≥3 prior platinum-based therapies, % (n)
43.4 (46)
27.1 (102)
PFI from last platinum-based therapy, % (n)
>12 months
21.7 (23)
34.2 (129)
6–12 months
52.8 (56)
40.3 (152)
<6 months
25.5 (27)
23.9 (90)
Missing
0
1.6 (6)
Platinum response to last therapy, % (n)
Sensitive
†
74.5 (79)
75.1 (283)
Resistant
‡
18.9 (20)
17.8 (67)
Refractory
§
6.6 (7)
6.9 (26)
Unknown
0
0.3 (1)
Oza AM et al.
Gynecol Oncol
. 2017;147:267–275.
10
Baseline Characteristics of the Efficacy and Safety Populations(2)